In response to the ongoing pandemic, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) founded a COVID-19 Task Force. Their primary objective is to provide information on population screening, diagnosis, biosafety guidelines for clinical laboratories, and recommendations on biochemical monitoring of hospitalized patients suffering from COVID-19. The task force recently published a preliminary guideline for serologic testing of antibodies to SARS-CoV-2 to assist clinical laboratories around the world.
The evidence-based recommendations, published in CCLM online October 6, 2020, provide preliminary guidance on clinical indications and target populations, on assay selection, verification of regulatory-approved assays, as well as on interpretation and limitations of serologic tests for antibodies to SARS-CoV-2 infection.
For further information, please follow the link to the (freely available) publication: https://www.ifcc.org/media/478651/14374331-clinical-chemistry-and-laboratory-medicine-cclm-ifcc-interim-guidelines-on-serological-testing-of-antibodies-against-sars-cov-2.pdf